Inhibikase Therapeutics (NASDAQ: IKT) is a clinical-stage biopharmaceutical company developing protein kinase inhibitor drug candidates for neurodegeneration and cardiovascular disease. The company generates no product revenue and funds operations through equity issuances, including common stock, pre-funded warrants, and warrants. Inhibikase was founded in September 2008 as a Georgia limited liability company, completed its IPO in 2020, and is listed on Nasdaq under the symbol IKT. Its lead program as of the 10-K filed March 26, 2026 is IKT-001, focused on pulmonary arterial hypertension (PAH), after the company paused development of risvodetinib in January 2025. In February 2025, the company acquired CorHepta Pharmaceuticals, Inc. to expand its pipeline. A Phase 2b/3 PAH study, IMPROVE-PAH, is under way, with contracted CRO costs of approximately $25.5 million and clinical supply commitments of approximately $6.3 million remaining as of December 31, 2025.

Revenue model

Pre-revenue clinical-stage company. Operations are financed by equity capital raises, including issuances of common stock, pre-funded warrants, and warrants. No product sales or licensing revenue are disclosed in the filing excerpts.

Products and services

IKT-001: lead kinase inhibitor candidate in Phase 2b/3 development for pulmonary arterial hypertension (IMPROVE-PAH study). Risvodetinib: kinase inhibitor candidate whose development was paused in January 2025. Pipeline expanded via acquisition of CorHepta Pharmaceuticals in February 2025. Original platform based on protein kinase inhibitors initially developed for bacterial and viral infectious diseases, later redirected toward neurodegeneration and cardiovascular disease.

Customers and end markets

No commercial customers. End markets targeted are pulmonary arterial hypertension and neurodegeneration. Drug candidates are in clinical development and have not received regulatory approval as of the filing date.

Value-chain role

Drug developer operating at the discovery and clinical-stage portion of the pharmaceutical value chain. Relies on contract research organizations (CROs) and clinical trial supply organizations for trial execution. Does not manufacture or commercialize products.

Geographic exposure

Headquartered in the United States. Clinical and regulatory activities directed at the FDA. No international commercial operations disclosed in the filing excerpts.

Source: SEC 10-K, filed 2026-03-26

Industry: Biological Products, (No Diagnostic Substances) Peers: REGENERX BIOPHARMACEUTICALS INC Sio Gene Therapies Inc. Bio Path Holdings Inc Onconetix Inc Cellectar Biosciences Inc Soligenix Inc Forte Biosciences Inc THERALINK TECHNOLOGIES, INC.